Seeking Alpha

Ziopharm Oncology (ZIOP -6.2%) drops following a blog report in Forbes.com that accuses the...

Ziopharm Oncology (ZIOP -6.2%) drops following a blog report in Forbes.com that accuses the company of failing to disclose an FDA warning letter. The blogger, an investor short on the stock, says the FDA admonished a clinical investigator hired by ZIOP for multiple violations in a mid-stage study of Palifosfamide, its investigational cancer drug. The study in question has since advanced into a late-stage trial with results expected before 2013.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector